Reference health
Copper Ions and Parkinson’s Disease: Why Is Homeostasis So Relevant?
90/90 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
3 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 90 checked references that resolve
resolves10.1007/s10653-011-9373-7
Bioelements and mineral matter in human livers from the highly industrialized region of the Upper Silesia Coal Basin (Poland)
resolves10.1016/j.neuint.2015.07.006
Copper at synapse: Release, binding and modulation of neurotransmission
resolves10.1042/CS20150153
Copper dyshomoeostasis in Parkinson's disease: implications for pathogenesis and indications for novel therapeutics
resolves10.1126/science.284.5415.805
Undetectable Intracellular Free Copper: The Requirement of a Copper Chaperone for Superoxide Dismutase
resolves10.1016/j.febslet.2013.05.019
Copper chaperones. The concept of conformational control in the metabolism of copper
resolves10.1038/nrneurol.2010.180
ATP7A-related copper transport diseases—emerging concepts and future trends
resolves10.14336/AD.2017.1018
Superoxide Radical Dismutation as New Therapeutic Strategy in Parkinson’s Disease
resolves10.1111/j.1600-0404.1989.tb01782.x
Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration?
resolves10.1111/j.1471-4159.1989.tb09150.x
Transition Metals, Ferritin, Glutathione, and Ascorbic Acid in Parkinsonian Brains
resolves10.1016/0304-3940(82)90390-1
Parkinson's disease: A disorder due to nigral glutathione deficiency?
resolves10.1017/S0317167100030584
Facteurs environnementaux dans l'étiologie de la maladie de Parkinson
resolves10.1002/mds.870080116
Parkinson's disease mortality and the industrial use of heavy metals in Michigan
resolves10.1212/WNL.48.3.650
Occupational exposures to metals as risk factors for Parkinson's disease
resolves10.2174/0929867325666171129124616
Metals and Parkinson's Disease: Mechanisms and Biochemical Processes
resolves10.1002/jat.1460
Mechanisms underlying the inhibition of the cytochrome P450 system by copper ions
resolves10.1016/0006-2952(85)90710-5
Effects of heavy metal cations, sulfhydryl reagents and other chemical agents on striatal D2 dopamine receptors
resolves10.1016/j.arr.2013.12.009
Are dopamine derivatives implicated in the pathogenesis of Parkinson's disease?
resolves10.1002/anie.201811122
Dopamine, Oxidative Stress and Protein–Quinone Modifications in Parkinson's and Other Neurodegenerative Diseases
resolves10.1016/j.jinorgbio.2014.03.018
Cu(II)-catalyzed oxidation of dopamine in aqueous solutions: Mechanism and kinetics
resolves10.1016/j.jtemb.2013.09.006
Assessment of trace elements in human brain using inductively coupled plasma mass spectrometry
resolves10.1073/pnas.1009932108
Calcium-dependent copper redistributions in neuronal cells revealed by a fluorescent copper sensor and X-ray fluorescence microscopy
resolves10.1089/ars.2015.6343
Alpha-Synuclein Oligomers Interact with Metal Ions to Induce Oxidative Stress and Neuronal Death in Parkinson's Disease
resolves10.1007/s10571-018-0587-4
Parkinson Disease from Mendelian Forms to Genetic Susceptibility: New Molecular Insights into the Neurodegeneration Process
resolves10.1096/fj.08-119784
Structural insights on physiological functions and pathological effects of ±‐synuclein
resolves10.1074/jbc.M105343200
Metal-triggered Structural Transformations, Aggregation, and Fibrillation of Human α-Synuclein
resolves10.1021/ja0618649
Interaction of α-Synuclein with Divalent Metal Ions Reveals Key Differences: A Link between Structure, Binding Specificity and Fibrillation Enhancement
resolves10.1039/C7MT00046D
Cross talk between neurometals and amyloidogenic proteins at the synapse and the pathogenesis of neurodegenerative diseases
resolves10.1073/pnas.0407881102
Structural characterization of copper(II) binding to α-synuclein: Insights into the bioinorganic chemistry of Parkinson's disease
resolves10.1016/j.bbrc.2007.05.060
Thermodynamics imprinting reveals differential binding of metals to α-synuclein: Relevance to parkinson’s disease
resolves10.1021/ja107842f
Exploring the Structural Details of Cu(I) Binding to α-Synuclein by NMR Spectroscopy
resolves10.1021/ja103338n
Structural Characterization of a High Affinity Mononuclear Site in the Copper(II)-α-Synuclein Complex
resolves10.1021/bi101912q
Coordination Features and Affinity of the Cu<sup>2+</sup> Site in the α-Synuclein Protein of Parkinson’s Disease
resolves10.1016/j.jinorgbio.2016.04.012
Coordination and redox properties of copper interaction with α-synuclein
resolves10.1021/ic302050m
Copper(I)-α-Synuclein Interaction: Structural Description of Two Independent and Competing Metal Binding Sites
resolves10.1074/jbc.M600933200
Phosphorylation of Ser-129 Is the Dominant Pathological Modification of α-Synuclein in Familial and Sporadic Lewy Body Disease
resolves10.1038/nature10324
α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation
resolves10.1002/pro.2088
N‐terminal acetylation of α‐synuclein induces increased transient helical propensity and decreased aggregation rates in the intrinsically disordered monomer
resolves10.1021/bi300642h
Impact of N-Terminal Acetylation of α-Synuclein on Its Random Coil and Lipid Binding Properties
resolves10.1074/jbc.M113.512459
N-terminal Acetylation Stabilizes N-terminal Helicity in Lipid- and Micelle-bound α-Synuclein and Increases Its Affinity for Physiological Membranes
resolves10.1021/jacs.5b01911
Copper Binding to the N-Terminally Acetylated, Naturally Occurring Form of Alpha-Synuclein Induces Local Helical Folding
resolves10.1021/acs.biochem.6b00708
Copper Binding and Subsequent Aggregation of α-Synuclein Are Modulated by N-Terminal Acetylation and Ablated by the H50Q Missense Mutation
resolves10.1039/c1mt00106j
Role of metal ions in aggregation of intrinsically disordered proteins in neurodegenerative diseases
resolves10.1007/s12017-009-8082-1
Interaction Between α-Synuclein and Metal Ions, Still Looking for a Role in the Pathogenesis of Parkinson’s Disease
resolves10.1016/j.neures.2017.11.011
A low blood copper concentration is a co-morbidity burden factor in Parkinson’s disease development
resolves10.1016/j.parkreldis.2018.05.022
Association of metals with the risk and clinical characteristics of Parkinson's disease
resolves10.1111/j.1471-4159.1989.tb07264.x
Increased Nigral Iron Content and Alterations in Other Metal Ions Occurring in Brain in Parkinson's Disease
resolves10.1017/S0317167100029140
Regional Metal Concentrations in Parkinson's Disease, Other Chronic Neurological Diseases, and Control Brains
resolves10.1016/S0006-8993(96)00782-2
Increased regional brain concentrations of ceruloplasmin in neurodegenerative disorders
resolves10.1016/j.neurobiolaging.2013.09.034
Copper pathology in vulnerable brain regions in Parkinson's disease
resolves10.1093/ajcn/67.5.972S
Aceruloplasminemia: an inherited neurodegenerative disease with impairment of iron homeostasis
resolves10.1523/JNEUROSCI.22-15-06578.2002
Ceruloplasmin Regulates Iron Levels in the CNS and Prevents Free Radical Injury
resolves10.1196/annals.1306.024
Aceruloplasminemia: An Inherited Neurodegenerative Disease with Impairment of Iron Homeostasis
resolves10.1007/s00401-017-1726-6
Amyotrophic lateral sclerosis-like superoxide dismutase 1 proteinopathy is associated with neuronal loss in Parkinson’s disease brain
resolves10.1007/BF00571500
Cu/Zn superoxide dismutase-like immunoreactivity is present in Lewy bodies from Parkinson disease: a light and electron microscopic immunocytochemical study
resolves10.1002/elps.201500187
Reduced net charge and heterogeneity of p<i>I</i> isoforms in familial amyotrophic lateral sclerosis mutants of copper/zinc superoxide dismutase
resolves10.2174/1570159X13666151030102718
Anti-Oxidants in Parkinson's Disease Therapy: A Critical Point of View
resolves10.1089/ars.2013.5593
Targeting Chelatable Iron as a Therapeutic Modality in Parkinson's Disease
resolves10.1038/s41598-017-01402-2
Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson’s disease
resolves10.1007/s00702-006-0499-1
The copper chelator, D-penicillamine, does not attenuate MPTP induced dopamine depletion in mice
resolves10.1111/j.1600-0773.1995.tb00160.x
Depletion of Copper and Manganese in Brain after MPTP Treatment of Mice
resolves10.1016/j.jinorgbio.2017.02.020
A moderate metal-binding hydrazone meets the criteria for a bioinorganic approach towards Parkinson's disease: Therapeutic potential, blood-brain barrier crossing evaluation and preliminary toxicological studies
resolves10.1523/JNEUROSCI.4196-13.2014
Oral Treatment with CuII(atsm) Increases Mutant SOD1 In Vivo but Protects Motor Neurons and Improves the Phenotype of a Transgenic Mouse Model of Amyotrophic Lateral Sclerosis
resolves10.1016/j.nbd.2016.01.020
Copper delivery to the CNS by CuATSM effectively treats motor neuron disease in SODG93A mice co-expressing the Copper-Chaperone-for-SOD
resolves10.1038/srep42292
CuII(atsm) improves the neurological phenotype and survival of SOD1G93A mice and selectively increases enzymatically active SOD1 in the spinal cord
resolves10.1016/j.nucmedbio.2011.08.008
Radiolabeled Cu-ATSM as a novel indicator of overreduced intracellular state due to mitochondrial dysfunction: studies with mitochondrial DNA-less ρ0 cells and cybrids carrying MELAS mitochondrial DNA mutation
resolves10.1016/j.nucmedbio.2011.02.016
Evaluation of striatal oxidative stress in patients with Parkinson's disease using [62Cu]ATSM PET
resolves10.1084/jem.20112285
The hypoxia imaging agent CuII(atsm) is neuroprotective and improves motor and cognitive functions in multiple animal models of Parkinson’s disease
The 3 references without a DOI — listed, not checked
no DOI — not checkedCopper and copper nanoparticles toxicity and their impact on basic functions in the body
no DOI — not checkedNational Research Council (U.S.), and Committee on Copper in Drinking Water (2000). Copper in Drinking Water, National Academy Press.
no DOI — not checkedOccupational exposure to manganese, copper, lead, iron, mercury and zinc and the risk of parkinson’s disease
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.3390/biom10020195"><img src="https://citestamp.com/citestamped/10.3390/biom10020195/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.3390/biom10020195)